Strong demand pushes Monopar Therapeutics stock higher in an extended rally

Traders Union
All News
Financial News
Monopar Therapeutics jumps 3.91% today

Highlights

MNPR/USD maintains a bullish trajectory, trading above short-, medium-, and long-term moving averages on key timeframes.
Momentum and trend indicators signal strong buying pressure, though overbought conditions and mixed oscillators suggest caution near current highs.
Expected trading range is $66.5498 to $73.0702 over the next 2–3 days, with a 78% probability of further upside.

Upward momentum persists as intraday volatility fuels overbought signals

On the hourly chart, MNPR has decisively moved above the MA-20 and MA-50, confirming near-term momentum, while on the daily timeframe it continues to trade above the MA-200. The Ichimoku Kijun sits at $64.89, providing a clear support level. Momentum indicators show mixed readings: MACD and ADX reflect bullish conditions, while RSI stands at 71.25, signifying overbought territory. Both CCI and BBP are also in overbought zones, whereas the Stoch RSI flags a strong sell, indicating oscillator divergence. The Awesome Oscillator corroborates the prevailing upward trend. The price opened with a gap of 0.195 and currently trades near the day's high, with heightened volatility indicating active intraday buying pressure, as supported by BBP.

Consolidation expected as scenario hinges on resistance and support

For the next 2 to 3 trading days, the expected range for MNPR is $66.5498 to $73.0702. The probability of further upside stands at 78%, with only a 22% likelihood of a downward move. The baseline scenario anticipates consolidation within this volatility band. If resistance is breached, a bullish breakout toward the upper boundary is likely, while a move below support at the Kijun level would open the door to a short-term retracement.

Anton Kharitonov, expert at Traders Union, sees the current technical setup for MNPR as bullish but unsustainable in the short term. He believes momentum indicators show optimism, yet the strong overbought readings and oscillator divergence demand caution. Price action may consolidate, but failure at support could trigger a retracement. "Until MNPR confirms support above $64.89, I remain cautious on chasing further upside."

Earlier, analysts noted that Monopar Therapeutics was exhibiting a bullish bias with momentum supported by key technical indicators. With MNPR now maintaining strength above major moving averages despite mixed oscillator signals, traders should monitor for a confirmed breakout above the current range, as a move higher could trigger a new leg of upside volatility.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.